Gene · 5732
PTGER2: prostaglandin E receptor 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PTGER2: prostaglandin E receptor 2. Genes, record 5732. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5732
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P43116 | Prostaglandin E2 receptor EP2 subtype | 358 | 5 | Ensembl, GeneID, HGNC |
Source UniProt
Patents30
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 59402 | P43116 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 3620 | P43116 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 3620 | P43116 | Espacenet |
| EP 4491229 A2 | 2025-01-15 | 207 | P43116 | Espacenet |
| WO 2024230934 A1 | 2024-11-14 | 332 | P43116 | Espacenet |
| US 12006548 B2 | 2024-06-11 | 471 | P43116 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 67454 | P43116 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 343 | P43116 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 170425 | P43116 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 9119 | P43116 | Espacenet |
1 to 10 of 30
See all 30 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ALPROSTADIL | CHEMBL495 | Prostanoid EP2 receptor agonist | AGONIST | ChEMBL |
| DINOPROSTONE | CHEMBL548 | Prostaglandin E2 receptor agonist | AGONIST | ChEMBL |
| EVATANEPAG | CHEMBL563646 | Prostanoid EP2 receptor agonist | AGONIST | ChEMBL |
| OMIDENEPAG | CHEMBL3707245 | Prostanoid EP2 receptor agonist | AGONIST | ChEMBL |
| OMIDENEPAG ISOPROPYL | CHEMBL4297666 | Prostanoid EP2 receptor agonist | AGONIST | ChEMBL |
| SIMENEPAG ISOPROPYL | CHEMBL2105710 | Prostanoid EP2 receptor agonist | AGONIST | ChEMBL |
| TAPRENEPAG ISOPROPYL | CHEMBL2105692 | Prostanoid EP2 receptor agonist | AGONIST | ChEMBL |
Trials51
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07601646 | ALPROSTADIL | PHASE2 | ClinicalTrials.gov | |
| NCT06768177 | ALPROSTADIL | ClinicalTrials.gov | ||
| NCT05774236 | DINOPROSTONE | PHASE3 | ClinicalTrials.gov | |
| NCT05761418 | DINOPROSTONE | PHASE3 | ClinicalTrials.gov | |
| NCT05342467 | DINOPROSTONE | PHASE2 | ClinicalTrials.gov | |
| NCT04536363 | ALPROSTADIL | PHASE2 | ClinicalTrials.gov | |
| NCT04505943 | DINOPROSTONE | ClinicalTrials.gov | ||
| NCT04505917 | DINOPROSTONE | ClinicalTrials.gov | ||
| NCT04301349 | DINOPROSTONE | PHASE3 | ClinicalTrials.gov | |
| NCT04299854 | DINOPROSTONE | ClinicalTrials.gov |
1 to 10 of 51
See all 51 trialsNIH grants1,955
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PTGER2 papers | Newest fiscal year |
|---|---|---|---|
| R01HL058506 | G Protein-Coupled Receptor Regulation in Airway Myocytes | 15 | 2025 |
| R01NS100947 | Inflammatory regulation of epileptogenesis after status epilepticus | 14 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 13 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 9 | 2025 |
| R01MH052716 | Neuroinflammation, Epigenetics and Male Vulnerability | 8 | 2025 |
| R01AI078908 | Control of Pulmonary Inflammation by Leukotriene E4 | 7 | 2025 |
| P30CA134274 | UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANT | 6 | 2025 |
| T32HL007749 | Multidisciplinary Training Program in Lung Disease | 6 | 2025 |
| U19AI095219 | Pathophysiologic and Therapeutic Mechanisms of Aspirin Exacerbated Respiratory Disease | 6 | 2025 |
| P01AI039671 | Costimulatory Mechanisms of Autoimmunity | 5 | 2025 |
1 to 10 of 1,955Source NIH's project files
See all 1,955 nih grantsPapers3,629
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting EP2 overcomes osimertinib-tolerant persisters through metabolic and inflammatory reprogramming in non-small cell lung cancer. | Int Immunopharmacol | 2026 | 42647987 | PubTator, text mining | PubMed |
| A Three-Dimensional Hyaluronic Acid-Based Scaffold Model for Electroporation-Enhanced Resveratrol Therapy in Triple-Negative Breast Cancer. | Cell Biochem Biophys | 2026 | 42599649 | PubTator, text mining | PubMed |
| IFI30 reprograms glioblastoma-associated macrophage and induces immune evasion by MAFF/PTGS2 pathway. | Acta Pharm Sin B | 2026 | 42592170 | PubTator, text mining | PubMed |
| Non-Invasive Physical Plasma Regulates COX-2 via EP2/EP4 Expression in Periodontal Ligament Cells Under Inflammatory Conditions. | Int J Mol Sci | 2026 | 42589366 | PubTator, text mining | PubMed |
| Correction: Engineering with EP2/EP4 knockout and IL-15 transpresentation renders stem cell-derived NK cells self-persistent and resistant to PGE2 inhibition. | Front Immunol | 2026 | 42582636 | PubTator, text mining | PubMed |
| Immune cells harbor their own microbiome-derived metabolome: a new layer of immunometabolic regulation. | Front Immunol | 2026 | 42582102 | PubTator, text mining | PubMed |
| A Functional Variant of CYP4V2 Contributes to Asthma Susceptibility Through Methylation-Mediated Regulation of the Arachidonic Acid Pathway. | J Asthma Allergy | 2026 | 42540736 | PubTator, text mining | PubMed |
| The dual pathological roles and targeted therapy of PGE2: from receptor signaling networks to disease microenvironment modulation. | Front Pharmacol | 2026 | 42528719 | PubTator, text mining | PubMed |
| The update of prostaglandin E2 receptor subtype 4 (EP4) in inflammatory diseases. | Genes Dis | 2026 | 42494643 | PubTator, text mining | PubMed |
Crocus sativus L.-derived lauric acid-functionalized gold nanoparticles induce ferroptosis in HeLa cells and reverse M2 macrophage polarization via the PGE2/EP2/cAMP-PKA signaling pathway: a network pharmacology-based study. | Front Pharmacol | 2026 | 42482776 | PubTator, text mining | PubMed |
1 to 10 of 3,629
See all 3,629 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5732
GET https://conductscience.org/api/genes/v1/5732/patents?page=2